IMDX
NASDAQ · Biotechnology
Insight Molecular Diagnostic
$2.31
-0.08 (-3.35%)
Financial Highlights (FY 2026)
Revenue
4.29M
Net Income
-53,073,758
Gross Margin
56.7%
Profit Margin
-1,238.5%
Rev Growth
+61.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 56.7% | 56.7% | 28.9% | 28.9% |
| Operating Margin | -1,260.8% | -1,134.7% | 34.3% | 33.1% |
| Profit Margin | -1,238.5% | -1,176.6% | 19.5% | 25.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.29M | 2.65M | 22.03M | 22.77M |
| Gross Profit | 2.43M | 1.50M | 6.37M | 6.58M |
| Operating Income | -54,045,490 | -30,090,282 | 7.55M | 7.53M |
| Net Income | -53,073,758 | -29,549,262 | 4.29M | 5.70M |
| Gross Margin | 56.7% | 56.7% | 28.9% | 28.9% |
| Operating Margin | -1,260.8% | -1,134.7% | 34.3% | 33.1% |
| Profit Margin | -1,238.5% | -1,176.6% | 19.5% | 25.1% |
| Rev Growth | +61.7% | +61.7% | +9.7% | +22.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 89.77M | 100.88M |
| Total Equity | — | — | 88.43M | 94.78M |
| D/E Ratio | — | — | 1.02 | 1.06 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -51,798,365 | -30,441,352 | 9.08M | 9.52M |
| Free Cash Flow | — | — | 3.08M | 2.32M |